SpringWorks 治疗主任卖掉近36%的股份 价值287万美元 在公司负收入中 SpringWorks Therapeutics Director sells nearly 36% of his shares for $2.87 million amid company's negative earnings.

SpringWorks 治疗主任Daniel Lynch最近出售了47 600股股份,以287万美元的价格将他的股份减少了36.46%。 SpringWorks Therapeutics Director Daniel Lynch recently sold 47,600 shares, reducing his holdings by 36.46%, for $2.87 million. 这是继最近另外两笔销售之后进行的。 This followed two other recent sales. SpringWorks是一家开发稀有疾病和癌症治疗的生物制药公司,报告季度收入为负数。 SpringWorks, a biopharmaceutical company developing treatments for rare diseases and cancer, reported negative quarterly earnings. 各种机构投资者还购买或出售股份,表明对公司兴趣混杂。 Various institutional investors have also bought or sold shares, showing mixed interest in the company.